<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925323</url>
  </required_header>
  <id_info>
    <org_study_id>2020-33</org_study_id>
    <secondary_id>2020-A01599-30</secondary_id>
    <nct_id>NCT04925323</nct_id>
  </id_info>
  <brief_title>A DERMO-EPIDERMAL AUTOLOGOUS SKIN SUBSTITUTE FOR FURTHER THERAPEUTIC USE</brief_title>
  <acronym>BIOPSKIN</acronym>
  <official_title>VALIDATION OF A GMP-COMPLIANT BIOPRINTING PROCESS FOR MANUFACTURING A DERMO-EPIDERMAL AUTOLOGOUS SKIN SUBSTITUTE FOR FURTHER THERAPEUTIC USE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Innovative technologies in the emerging field of regenerative medicine might allow an&#xD;
      improvement in the treatment of deep complex wounds leading to faster and better wound&#xD;
      healing. Among them, the bioprinting technology, consisting in &quot;printing human cells and&#xD;
      biomaterials&quot; to create a &quot;dermo-epidermal substitute&quot; that mimics an alternative of the&#xD;
      physiological skin is the most promising alternative.&#xD;
&#xD;
      Besides improving skin substitutes properties, bioprinting allows to translate the&#xD;
      manufacturing process of tissue-engineered products from manual, operator-dependent processes&#xD;
      to a reproducible and automated solution. This paves the way to the manufacturing of&#xD;
      therapeutic bioprinted products at the point of care, as close as possible from patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this preclinical in vitro study, the investigators plan to generate GMP-compliant&#xD;
      validation batches of &quot;bio-printed dermo-epidermal substitutes&quot; from 25 healthy volunteer&#xD;
      patients' unused surgical tissue removed during plastic surgeries.&#xD;
&#xD;
      Volunteer's harvested tissue will allow to extract and then amplify the epidermal&#xD;
      keratinocytes and dermal fibroblasts. Successive cultures and bioprinting steps will generate&#xD;
      a &quot;bio-printed dermo-epidermal substitute&quot; in 2 or 3 weeks. A blood test may also be&#xD;
      performed on the volunteers to characterize the genetic stability during the different stages&#xD;
      of the process.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bioprinted dermo epidermal substitute sterility assessment</measure>
    <time_frame>24 MONTHS</time_frame>
    <description>Culture media from dermo-epidermal bioprinted substitutes were sampled in Bactec culture bottles (Peds Plus Aerobic/F and Plus Anaerobic/F culture vials, containing each 40 mL of medium). The Bactec method (Becton Dickinson, Sparks, MD, USA) uses a computer-controlled incubation/detection system. The media used contained proprietary factors designed to inactivate a wide variety of antibacterial and antifungal agents. Bactec culture bottles were incubated at 37 °C for a total of 10 days, and automated readings were taken every 10 min. Detection of organisms resulted in an audible alarm and automatic recording of time to detection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Population Doubling Rate of keratinocytes</measure>
    <time_frame>24 MONTHS</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Population Doubling Rate of fibroblasts</measure>
    <time_frame>24MONTHS</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Plastic Surgeries</condition>
  <arm_group>
    <arm_group_label>a plastic or repair surgery indication generating surgical waste</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BLOOD SAMPLES</intervention_name>
    <description>BLOOD SAMPLES</description>
    <arm_group_label>a plastic or repair surgery indication generating surgical waste</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>surgical tissue samples</intervention_name>
    <description>unused surgical tissue removed during plastic surgeries</description>
    <arm_group_label>a plastic or repair surgery indication generating surgical waste</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult adult males or females&#xD;
&#xD;
          -  Members of a social security scheme.&#xD;
&#xD;
          -  No contraindications to general anesthesia&#xD;
&#xD;
          -  Relevant to a plastic or repair surgery indication generating surgical waste.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and/or nursing women&#xD;
&#xD;
          -  Persons deprived of liberty&#xD;
&#xD;
          -  Major under guardianship&#xD;
&#xD;
          -  Persons unable to read the backgrounder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-olivier ARNAUD</last_name>
    <role>Study Director</role>
    <affiliation>AP HM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique CASANOVA</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP HM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique CASANOVA</last_name>
    <phone>04 91 35 38 55</phone>
    <email>dominique.casanova@ap-hm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>baptiste BERTRAND</last_name>
    <phone>04.91.35.38.55</phone>
    <email>baptiste.bertrand@ap-hm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>assistance publique hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>dominique casanova</last_name>
      <email>dominique.casanova@ap-hm.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

